Lonza says in talks to buy Capsugel; deal could top $5bn

Swiss pharmaceutical manufacturer Lonza Group AG on Monday confirmed it is in advanced talks with private equity firm KKR & Co LP to acquire Capsugel, a U.S. maker of capsule products and other drug delivery systems.

Sources familiar with the talks told Reuters that a potential transaction would be valued at more than $5 billion.

Capsugel "would fit perfectly with Lonza's ... strategy and strengthen its position as leading supplier to a number of important healthcare markets," Lonza said in a statement. "A successful acquisition would be value adding and be within Lonza's stated acquisition criteria."

The deal, which Lonza said still may not come to fruition, comes as the Swiss drug ingredient maker seeks to boost its life sciences capabilities and produce a wider range of molecules used in active pharmaceutical ingredients and drug delivery. It held unsuccessful talks to acquire U.S. drug delivery technology company Catalent Inc earlier this year.

Discussions between Lonza and KKR could lead to a deal as early this week, people familiar with the talks said on Sunday.

The sources asked not to be identified because the negotiations are confidential. Capsugel and KKR did not immediately respond to requests for comment.

Based in Morristown, New Jersey, Capsugel manufacturers empty two-piece hard capsules as well as finished dosage forms for drug delivery. It serves more than 4,000 corporate customers in over 100 countries.

Reuters reported in March that KKR was preparing to run a sale process for Capsugel this year, and also explore the possibility of an initial public offering of the company as an alternative to an outright sale.

KKR acquired Capsugel from Pfizer Inc for $2.4 billion in 2011.

Lonza has been expanding its presence in the United States in recent years, buying up small biopharmaceutical companies and in 2011 acquiring chemical maker Arch Chemicals for $1.4 billion. Lonza has a market capitalization of 9.4 billion Swiss francs ($9.25 billion). (Source: Reuters)

Disclaimer
The information on this page may have been provided by a contributor to ChinaGoAbroad, and ChinaGoAbroad makes no guarantees about the accuracy of any content. All content shall be used for informational purposes only. Contributors must obtain all necessary licenses and/or ownership rights from the relevant content owner(s) before submitting such content (including texts, pictures, photos and diagrams) to ChinaGoAbroad for publication. ChinaGoAbroad disclaims all liability arising from the publication of any content/information (such as texts, pictures, photos and diagrams that infringe on any copyright) received from contributors. Links may direct to third party sites out of the control of ChinaGoAbroad, and such links shall not be considered an endorsement by ChinaGoAbroad of any information contained on such third party sites. Please refer to our Disclaimer for more details.

Source

Lonza Group Ltd

Tags

Regions & Countries
SwitzerlandUSA
Industries
Pharma/Biotech

Other Member Updates

Top